Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
Acta Oncologica (Stockholm, Sweden)|May 31, 2014
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinibBenoit Beuselinck, Diether Lambrechts, Thomas Van Brussel, et al.
Journal for Immunotherapy of Cancer|November 7, 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinomaManon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyAndrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Pharmacoepidemiology and Drug Safety|June 3, 2017
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort studyPernelle Noize, Angela Grelaud, Jacques-Olivier Bay, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX studyAlain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Eleonora Mauric, Alice Tison, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
Journal for Immunotherapy of Cancer|May 26, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinomaJulius Strauss, Jean-Laurent Deville, Mario Sznol, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|December 9, 2017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialManish R Patel, John Ellerton, Jeffrey R Infante, et al.
Acta Oncologica (Stockholm, Sweden)|May 31, 2014
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinibBenoit Beuselinck, Diether Lambrechts, Thomas Van Brussel, et al.
Journal for Immunotherapy of Cancer|November 7, 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinomaManon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib StudyAndrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Pharmacoepidemiology and Drug Safety|June 3, 2017
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort studyPernelle Noize, Angela Grelaud, Jacques-Olivier Bay, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX studyAlain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Eleonora Mauric, Alice Tison, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
Journal for Immunotherapy of Cancer|May 26, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinomaJulius Strauss, Jean-Laurent Deville, Mario Sznol, et al.
Pageof 23